{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:51:53Z","timestamp":1790682713961,"version":"4.1.0"},"reference-count":40,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,4]]},"DOI":"10.2967\/jnumed.124.269252","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:40:12Z","timestamp":1740073212000},"page":"572-578","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Trial Protocol for LuCAB: A Phase I\u2013II Trial Evaluating Cabazitaxel in Combination with [<sup>177<\/sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Louise","family":"Kostos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B.","family":"Haskali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025040211001538000_66.4.572.1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet."},{"key":"2025040211001538000_66.4.572.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025040211001538000_66.4.572.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025040211001538000_66.4.572.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2025040211001538000_66.4.572.5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025040211001538000_66.4.572.6","doi-asserted-by":"crossref","first-page":"17588359231179309","DOI":"10.1177\/17588359231179309","article-title":"Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Kostos","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2025040211001538000_66.4.572.7","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1200\/JCO.2024.42.4_suppl.175","article-title":"Outcomes for patients with mCRPC and liver metastasis receiving 177Lu-PSMA-617 treatment [abstract]","volume":"42","author":"Muniz","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266167"},{"key":"2025040211001538000_66.4.572.9","doi-asserted-by":"crossref","first-page":"S5055","DOI":"10.1200\/JCO.2024.42.16_suppl.5055","article-title":"Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) [abstract]","volume":"42","author":"Kwan","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2012.05.008","article-title":"Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment","volume":"49","author":"Rohrer Bley","year":"2013","journal-title":"Eur J Cancer."},{"key":"2025040211001538000_66.4.572.11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/CAD.0000000000000055","article-title":"Taxanes as radiosensitizers","volume":"25","author":"Golden","year":"2014","journal-title":"Anticancer Drugs."},{"key":"2025040211001538000_66.4.572.12","doi-asserted-by":"crossref","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","article-title":"Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"38","author":"Batra","year":"2020","journal-title":"Urol Oncol."},{"key":"2025040211001538000_66.4.572.13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s13139-021-00696-5","article-title":"The outcome and safety of re-challenge lutetium-177 PSMA (177Lu-PSMA) therapy with low-dose docetaxel as a radiosensitizer: a promising combination in metastatic castrate-resistant prostate cancer (mCRPC)\u2014a case report","volume":"55","author":"Maharaj","year":"2021","journal-title":"Nucl Med Mol Imaging."},{"key":"2025040211001538000_66.4.572.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025040211001538000_66.4.572.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.008"},{"key":"2025040211001538000_66.4.572.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233411"},{"key":"2025040211001538000_66.4.572.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025040211001538000_66.4.572.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2025040211001538000_66.4.572.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025040211001538000_66.4.572.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2025040211001538000_66.4.572.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05525-7"},{"key":"2025040211001538000_66.4.572.22","doi-asserted-by":"crossref","first-page":"S5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"2025040211001538000_66.4.572.24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025040211001538000_66.4.572.25","doi-asserted-by":"crossref","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","article-title":"AlphaBet: combination of r-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025040211001538000_66.4.572.26","doi-asserted-by":"crossref","first-page":"S5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.27","doi-asserted-by":"crossref","first-page":"TPS271","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS271","article-title":"Evolution: phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.28","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","article-title":"Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors","volume":"44","author":"Yordanova","year":"2019","journal-title":"Clin Nucl Med."},{"key":"2025040211001538000_66.4.572.29","doi-asserted-by":"crossref","first-page":"S4608","DOI":"10.1200\/JCO.2020.38.15_suppl.4608","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET study: phase II study evaluating the activity of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)\u2014first results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS) [abstract]","volume":"38","author":"Pavlakis","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025040211001538000_66.4.572.31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2025040211001538000_66.4.572.32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"key":"2025040211001538000_66.4.572.33","doi-asserted-by":"crossref","first-page":"S5075","DOI":"10.1200\/JCO.2024.42.16_suppl.5075","article-title":"Hematologic toxicity in 177Lu-PSMA-617 treatment for mCRPC: unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV) [abstract]","volume":"42","author":"Ghodsi","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025040211001538000_66.4.572.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1068"},{"key":"2025040211001538000_66.4.572.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1076"},{"key":"2025040211001538000_66.4.572.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0596"},{"key":"2025040211001538000_66.4.572.37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther."},{"key":"2025040211001538000_66.4.572.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"2025040211001538000_66.4.572.39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2025040211001538000_66.4.572.40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.269252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:05:26Z","timestamp":1743617126000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.269252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.2967\/jnumed.124.269252"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.269252","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}